JP Morgan Chase
CLGN icon

JP Morgan Chase’s CollPlant Biotechnologies CLGN Stock Holding History

JP Morgan Chase’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-371
Closed -$2.37K – 7465
2023
Q4 		$2.37K Buy
+371
New +$2.03K ﹤0.01% 6696

Other funds holding CLGN

PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

JP Morgan Chase's CLGN Position: Q1 2024 in Review

JP Morgan Chase sold out of CollPlant Biotechnologies (CLGN) in Q1 2024, closing a stake of 371 shares — an estimated $2.37K sold.

JP Morgan Chase first reported a position in CLGN in Q4 2023 and held it in 1 quarter. The position peaked at $2.37K in Q4 2023. 13 funds tracked by Wall St. Rank hold CLGN as of Q1 2024.

  • JP Morgan Chase reported no remaining CollPlant Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 371 CollPlant Biotechnologies shares in Q1 2024, an estimated $2.37K.
  • JP Morgan Chase first reported a position in CollPlant Biotechnologies in Q4 2023 and held it in 1 quarter.
  • JP Morgan Chase's CollPlant Biotechnologies position peaked at $2.37K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.